Research Evidence
The clinical evidence supporting semaglutide is extensive and robust, derived from multiple large-scale randomized controlled trials.
STEP Program Trials: The STEP (Semaglutide Treatment Effect in People with Obesity) program comprises several pivotal trials. STEP 1 enrolled 1,961 adults with obesity without diabetes, demonstrating 14.9% mean weight loss versus 2.4% with placebo over 68 weeks. STEP 2 focused on diabetic populations, showing 9.6% weight reduction alongside improved glycemic control.
SELECT Trial: The SELECT cardiovascular outcomes trial, published in 2023, demonstrated a 20% reduction in major adverse cardiovascular events in overweight/obese individuals without diabetes, establishing semaglutide's cardioprotective benefits independent of glycemic effects.
Emerging Research: Emerging research explores semaglutide's potential in non-alcoholic fatty liver disease (NAFLD), with early trials showing significant improvements in liver histology and fibrosis markers. Neurological applications including Alzheimer's disease and Parkinson's disease are under investigation based on observed neuroprotective mechanisms in preclinical models.
“The SELECT trial was a watershed moment — demonstrating a 20% reduction in major adverse cardiovascular events in patients without diabetes established that semaglutide's cardioprotective effects are independent of glycemic improvement, fundamentally expanding the clinical rationale for GLP-1 agonist therapy beyond metabolic disease.”
